Helixgate https://validator.w3.org/feed/docs/rss2.html Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more Home 7 companies hiring in New York now Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy Replimune’s twice-rejected melanoma drug prevails in FDA adcomm FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest Key Senate panel backs Trump’s picks for CDC, pandemic preparedness Judge denies states’ motion to postpone Medicaid work requirement Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts The lightbulb moment behind a potential antiviral breakthrough  Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate J&J secures right to take the helm in up to $925M Sail CAR T pact Ebola outbreak nears milestone, but vaccine is close  Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions Life after the lead asset: Advancing an early-stage pipeline Elix and University of Vienna Aim to Advance Drug Discovery Using AI Alnylam plunges as earnings deliver ‘one-two punch’ NSF testing new Ph.D. model giving trainees academic and industry experience A Computational Framework for Designing Disordered Proteins at Large Scale STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment Capricor Duchenne cell therapy voted down by FDA panel Genetic Study of Fibromyalgia Points to Neurological Basis Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption New funding, new jobs: 4 biotechs hiring after series B raises STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers Not-so-special delivery: When biopharmas fumble layoff news FDA adcomm shoots down Capricor’s Duchenne cell therapy after meeting marked by statistical dispute Caldera, Vidya add to recent flurry of biotech mergers Large Bioprinted Tissues Get a Precision Boost Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push Genome Mining Points to Less Toxic, More Potent Polyene Antifungals in Mice Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more Do you need oncology experience to land an oncology job? Sage Inks Publishing Deal with Causaly’s AI Platform Focusing on Drug Discovery Research Capricor’s data clash and a fugitive in the C-suite Phase I study for prevention of chemotherapy-induced peripheral neuropathy Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store Is it safe to drink Red Bull and vodka? Questionable research tied to energy drink giant has shaped policy A neglected issue in pedestrian, biker deaths Replimune melanoma drug wins support of FDA panel 2026 IPO stock tracker: How newly public biotechs are performing ERAD-level gene switches for on-demand protein secretion and rapidly controlled gene therapies Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function